26 May 2020, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, is pleased to announce that Medalchemy, the Group’s GMP certified manufacturing site in Alicante, Spain, will manufacture product for a clinical trial as part of a Consortium led by the University of Valencia. The clinical trial in COVID-19 patients will use the T12 molecule to prevent disease progression towards Adult Respiratory Distress Syndrome (‘ARDS’), which is believed to be the leading cause of death in COVID-19 patients. The T12 molecule targets Goodpasture antigen-binding protein (‘GPBP’), an extracellular protein kinase overexpressed in the lung, of COVID-19 patients which is suspected to enlarge alveolar septum causing poor blood oxygenation in ARDS induced by other pathogens.
With over a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs), Medalchemy is EMMAC’s research and development facility in Spain, one of its two GMP-Certified laboratories, in addition to Rokshaw Laboratories, in the UK.
Antonio Costanzo, CEO of EMMAC, said: “We are very pleased that through Medalchemy, our GMP-Certified laboratory in Spain, that we are able to support this urgent initiative. During these unprecedented times it is important Medalchemy is able to offer its wealth of expertise and facilities to support such vitally important advancements for us all.”
About EMMAC Life Sciences Group
EMMAC Life Sciences Group is Europe’s leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it.
For scientific enquiries please contact email@example.com
|Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz||Tel: +44 (0) 20 7466 5000|
All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.